ExxonMobil Investment Management’s St Jude Medical STJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-66,134
Closed -$5.3M 514
2016
Q4
$5.3M Sell
66,134
-6,619
-9% -$525K 0.12% 207
2016
Q3
$5.8M Sell
72,753
-832
-1% -$67.2K 0.12% 207
2016
Q2
$5.74M Buy
73,585
+4,531
+7% +$323K 0.12% 205
2016
Q1
$3.8M Buy
69,054
+5,698
+9% +$310K 0.09% 266
2015
Q4
$3.91M Sell
63,356
-1,321
-2% -$83.3K 0.1% 244
2015
Q3
$4.08M Buy
64,677
+2,491
+4% +$178K 0.1% 228
2015
Q2
$4.54M Sell
62,186
-5,458
-8% -$394K 0.11% 216
2015
Q1
$4.42M Buy
67,644
+237
+0.4% +$15.8K 0.1% 250
2014
Q4
$4.38M Sell
67,407
-2,355
-3% -$152K 0.1% 245
2014
Q3
$4.2M Sell
69,762
-2,551
-4% -$167K 0.1% 239
2014
Q2
$5.01M Sell
72,313
-2,013
-3% -$130K 0.11% 213
2014
Q1
$4.86M Sell
74,326
-1,636
-2% -$106K 0.11% 216
2013
Q4
$4.71M Sell
75,962
-391
-0.5% -$22.6K 0.11% 217
2013
Q3
$4.1M Sell
76,353
-2,386
-3% -$123K 0.1% 237
2013
Q2
$3.59M Buy
+78,739
New +$3.41M 0.09% 269

Other funds holding STJ

ExxonMobil Investment Management's STJ Position: Q1 2017 in Review

ExxonMobil Investment Management sold out of St Jude Medical (STJ) in Q1 2017, closing a stake of 66,134 shares — an estimated $5.3M sold.

ExxonMobil Investment Management first reported a position in STJ in Q2 2013 and held it in 15 quarters. The position peaked at $5.8M in Q3 2016. 4 funds tracked by Wall St. Rank hold STJ as of Q1 2017.

  • ExxonMobil Investment Management reported no remaining St Jude Medical position as of Q1 2017 after selling out during the quarter.
  • ExxonMobil Investment Management sold 66,134 St Jude Medical shares in Q1 2017, an estimated $5.3M.
  • ExxonMobil Investment Management first reported a position in St Jude Medical in Q2 2013 and held it in 15 quarters.
  • ExxonMobil Investment Management's St Jude Medical position peaked at $5.8M in Q3 2016.
  • 4 funds tracked by Wall St. Rank held St Jude Medical as of Q1 2017.

Based on ExxonMobil Investment Management's 13F filing for Q1 2017, filed 10 Apr 2017.